Lasa Supergenerics Ltd.

25.42 -0.35 ▼-1.4%

18 April 2024, 04:01:00 PM
Volume: 18,761

Company Profile

Sector Healthcare Sector Icon Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Industry Icon Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.lasalabs.com
Market Cap 125.40 Cr.
Enterprise Value(EV) 124.69 Cr. 2023-09
Financial Indicators
Earnings per share (EPS) -4.28 Trailing Twelve Months Ending 2023-12
Price-Earning Ratio (PE) - Trailing Twelve Months Ending 2023-12
Industry PE 41.01 Trailing Twelve Months Ending 2023-12
Book Value / Share 22.33 Trailing Twelve Months Ending 2023-12
Price to Book Value 1.12 Calculated using Price: 25.03
Dividend Yield 0.00 Period Ending 2023-03
No. of Shares Subscribed 5.01 Cr. 50,101,239 Shares
FaceValue 10
About Lasa Supergenerics Ltd.
The company is specialises in ‘catalyst chemistry' and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India

Lasa Supergenerics Ltd. Delivery

Delivered Qty
Traded Qty

Lasa Supergenerics Ltd. Performance

1 Day
-1.36%
1 Week
-0.12%
1 Month
+6.67%
3 Month
-21.59%
6 Month
-5.01%
1 Year
+11.15%
2 Year
-56.47%
5 Year
+6.58%
10 Year

Lasa Supergenerics Ltd. Fundamental Ratios

8 years 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03 2023-03
Return on Equity (%) 0 8.65 14.33 -10.81 2.94 15.17 -3.37 -27.97
Return on Capital Employed (%) 0 14.45 12.8 -3.73 6.77 17.14 -3.41 -23.94
Return on Assets (%) 0 2.07 4.79 -4.44 1.5 10.43 -2.56 -20.71

Lasa Supergenerics Ltd. Balance Sheet

Particulars 9 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-09* Rs. Cr.
Shh. Funds 0 75 117 105 141 159 158 118 113
Non Curr. Liab. 0 83 62 43 11 8 7 3 7
Curr. Liab. 70 107 107 76 41 45 43 46
Minority Int.
Equity & Liab. 0 228 287 255 229 208 209 164 166
Non Curr. Assets 149 178 170 153 144 143 125 120
Curr. Assets 0 79 109 86 76 64 66 39 45
Misc. Exp. not W/O 0
Total Assets 0 228 287 255 229 208 209 164 166

Lasa Supergenerics Ltd. Profit and Loss

Particulars 9 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr. 2023-12 Rs. Cr. TTM
Net Sales 199 244 170 167 202 137 130 117
Other Income 2 3 1 0 0 0 2 1
Total Income 201 247 170 167 203 137 131 118
Total Expenditure -153 -202 -159 -137 -155 -121 -136 -106
PBIDT 48 45 12 30 47 16 -5 12
Interest -12 -11 -8 -8 -2 0 -4 -2
Depreciation -8 -18 -19 -17 -16 -15 -13 -12
Taxation 0 -3 4 -1 -7 1 4 1
Exceptional Items -26 -8 -20 -20
PAT 2 12 -12 4 23 -5 -39 -21
Adjusted EPS 472 5 -5 1 6 -1 -8 -4

Lasa Supergenerics Ltd. Cash Flow

Particulars 8 years 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2023-03 Rs. Cr.
Cash Fr. Operatn. 0 -3 40 41 14 41 9 -17
Cash Fr. Inv. 0 -44 -7 -2 -4 -3 11
Cash Fr. Finan. 0 0 4 -33 -10 -36 0 -4
Net Change 0 -3 0 0 2 1 6 -10
Cash & Cash Eqvt 0 0 1 0 3 4 11 1

Lasa Supergenerics Ltd. Shareholding Pattern

9 Qtrs 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%) 2023-03 (%) 2023-06 (%) 2023-09 (%) 2023-12 (%) 2024-03 (%)
Promoter 43.78 43.78 43.78 43.78 53.65 53.65 53.65 53.65 53.65
Public 56.22 56.22 56.22 56.22 46.35 46.35 46.35 46.35 46.35
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 35.15 31.19 31.19 31.19 20.66 20.66 20.66 20.66 20.66
No. of Shareholders (in Lacs)

Lasa Supergenerics Ltd. Announcements

Mon, 15 Apr 2024
Compliance Under Reg 7(3) SEBI LODR Regulations 2015 For The Period Ended March 31 2024
Pursuant to Regulation 7 (3) of SEBI LODR Regulations 2015 We hereby confirm that all activities in relation to both physical and electronic share transfer facility during period 1st April 2023 to 31st March 2024 (both days inclusive) are maintained by our Registrar and Share Transfer Agent - BigShare Services Private Limited having permanant SEBI Registration No. INR000001385
Mon, 15 Apr 2024
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
Certificate under regulation 74 (5) SEBI (Depositories and Participants) Regulations 2018 for the quarter and the year ended March 31 2024 received from Bigshare Services Private Limited Registrar and Share Transfer Agent of the Company.
Fri, 29 Mar 2024
Closure of Trading Window
This is to Inform you that as per the company code of Conduct for Regulation Monitoring and Reporting of Trading by Insiders in terms of ( Prohibition of Insider Trading) Regulations 2015 as amended the Trading window for dealing of Equity Share of the Company has been closed for designated employee and their immediate relatives w.e.f 1st April 2024 to till the 48 hours after the declaration of Audited Financial result (both days inclusive) for the quarter and the year ended March 31 2024

Lasa Supergenerics Ltd. Technical Scans

Thu, 18 Apr 2024
High Delivery Percentage High Delivery Percentage
Higher Delivery Quantity Higher Delivery Quantity
Higher Delivery Quantity and Percentage Higher Delivery Quantity and Percentage
Higher Trade Quantity Higher Trade Quantity
Higher Trade and Delivery Quantity Higher Trade and Delivery Quantity

Lasa Supergenerics Ltd. Related Stocks

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 364,015.10 1,523.80 -0.9%
Cipla Ltd. 108,808.58 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. 99,408.67 5,959.10 -1.5%
Divi's Laboratories Ltd. 98,683.96 3,717.35 -1.3%
Mankind Pharma Ltd. 96,037.07 2,397.40 +5.0%
Zydus Lifesciences Ltd. 94,213.69 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. 87,250.69 6,107.00 -3.6%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 40.87 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-12 29.34 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 19.01 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-12 71.36 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-12 55.61 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 31.68 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 110.54 6,107.00 -3.6%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-12 5.83 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-12 4.20 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-12 3.70 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-12 7.57 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-12 10.81 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-12 5.00 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-12 12.92 6,107.00 -3.6%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 0.11 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 0.02 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 0.06 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 0.00 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 0.02 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 0.07 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 0.44 6,107.00 -3.6%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 12.85 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,107.00 -3.6%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 16.46 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 12.85 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 21.36 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 14.89 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 19.27 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 11.60 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 15.16 6,107.00 -3.6%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 43,885.68 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 22,753.12 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 24,669.70 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 7,767.51 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 8,749.43 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 17,237.40 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 16,612.50 6,107.00 -3.6%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2023-03 8,560.84 1,523.80 -0.9%
Cipla Ltd. Consolidated 2023-03 2,835.49 1,352.95 -1.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2023-03 4,507.30 5,959.10 -1.5%
Divi's Laboratories Ltd. Consolidated 2023-03 1,823.38 3,717.35 -1.3%
Mankind Pharma Ltd. Consolidated 2023-03 1,309.68 2,397.40 +5.0%
Zydus Lifesciences Ltd. Consolidated 2023-03 2,001.90 934.50 -1.1%
Apollo Hospitals Enterprise Ltd. Consolidated 2023-03 887.50 6,107.00 -3.6%

Lasa Supergenerics Ltd. FAQ's

What is Lasa Supergenerics share price?

Can I buy Lasa Supergenerics shares now?

What is the Market Cap of Lasa Supergenerics?

What are the key metrics to analyse Lasa Supergenerics?

What is the 52 Week High and Low of Lasa Supergenerics?

What is the trend of Lasa Supergenerics share price?